COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2018) Provider Type 32: Opioid Treatment Program

Similar documents
COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Jan 1, 2018)

Service Description Rate Unit Service Limits Combination of Service Rules

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Aug 1, 2017)

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Aug 1, 2017)

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2017)

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff May 15, 2017)

Medicaid Treatment and Service Fees for Substance Use Disorder (SUD): CY

2017 Drug Screen Tests

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee

MEDICAL POLICY Drug Testing

MEDICAL POLICY Drug Testing

Drug Testing Policy. Approved By 05/10/2017. Application This reimbursement policy applies to UnitedHealthcare Community Plan Medicaid products.

Opioid Treatment Program Reimbursement Re-bundling Proposal

Medical Policy Outpatient Drug Screening and Testing. No Prior Authorization X X

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: October 1, Related Policies None

MEDICAL POLICY No R2 DRUG TESTING

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: January 1, Related Policies None

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: March 1, Related Policies None

Payment Policy Drug Testing EFFECTIVE DATE: POLICY LAST UPDATED:

Drug Testing Policy. Approved By 06/14/2017

2017 Drug Screening Code Updates for WV Medicaid. Prior Authorization for Drug Screening Codes Beyond Service Limits

2018 Drug Screening Code Updates for WV Medicaid

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee

B. To assess an individual when clinical evaluation suggests use of non-prescribed medications or illegal substances; or

Prevention of Fetal Alcohol Spectrum Disorder Coding Basics

Clinical Drug Screening and/or Drug Testing

Clinical Drug Screening and/or Drug Testing

Addiction and Recovery Treatment Services (ARTS) Reimbursement Structure

MAGELLAN VA MEDICAID/DMAS RATES

MAGELLAN VA MEDICAID/DMAS RATES

distinguish between structural isomers (but not necessarily stereoisomers), including, but not

Controlled Substance Monitoring and Drugs of Abuse Testing Determination

DMHAS ASAM SERVICE DESCRIPTIONS

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

Calendar Year (CY) 2017 Clinical Laboratory Fee Schedule (CLFS) Final Determinations

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Cigna Medical Coverage Policy

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery

PROCEDURE CODES & UNIT

BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES

An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder

Based on our criteria and assessment of the peer-reviewed literature, presumptive (immunoassay) in office or pointof-care

In-OfficeLabTesting. Effective date: August 1, 2017

Clinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.

In Office Lab Testing

Clinical Policy: Outpatient Testing for Drugs of Abuse Reference Number: CP.MP.HN 542

Claims Edit Guideline: Drug Testing

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical UM Guideline

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016

Closing the Loop in Treating Opioid Addiction:

URINE DRUG TESTING FOR SUBSTANCE ABUSE TREATMENT AND CHRONIC PAIN MANAGEMENT

Urine Drug Testing for Substance Use and Pain Management

Clinical Policy: Buprenorphine-Naloxone (Suboxone, Bunavail, Zubsolv) Reference Number: CP.PMN.XX. Line of Business: Medicaid

Medicaid and the Opioid Crisis

VIRGINIA MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) OFFICE BASED OPIOID PROVIDER (OBOT) PAYMENT MODEL 3 rd Annual Mental Health Summit

Policy Evaluation: Substance Use Disorders

Medical Necessity Criteria 2017

See Important Reminder at the end of this policy for important regulatory and legal information.

Contractor Information. LCD Information

RI Centers of Excellence for the

Behavioral Health Authorization Requirements*

Medication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 Amended Date: 10/1/2015 DRAFT Table of Contents

Corporate Medical Policy

State Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment

VIRGINIA MEDICAID PERSPECTIVE ON BEST PRACTICES IN THE TREATMENT OF OPIOID USE DISORDER

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

State Opioid Response (SOR) Grant

New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS

The CARA & Buprenorphine Prescribing for APNs & PAs

Community Behavioral Health Services. Fee Schedule

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Frequently Asked Questions about Florida s Opioid STR Grant

Comment Number. Date Comment Received

Addiction Recovery Treatment Services (ARTS): Billing Best Practices. December 2017

PROCEDURE CODES & UNIT

PERSPECTIVE FROM VIRGINIA: SUCCESS ADDRESSING THE OPIOID CRISIS THROUGH MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS)

Vermont Hub and Spoke Model Treatment Need Questionnaire

Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine

Virginia Medicaid Peer Support Services UM Guideline

Management Options for Opioid Dependence:

Prepublication Requirements

Clinical Policy: Outpatient Testing for Drugs of Abuse

COURT OF COMMON PLEAS DRUG DIVERSION PROGRAM

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

Page 1 of 11. Effective 9/15/2018 AUTHORIZATION REQUIREMENT LEVEL OF CARE. Notes (0 = No Additional Comments)

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv)

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

ADDICTION AND RECOVERY OPIOID CRISIS

Medication-Assisted Treatment (MAT) Overview

Improving the Quality of Addiction Treatment

Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction

Coding for Preventive Services A Guide for HIV Providers

Transcription:

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2018) Provider Type 32: Opioid Treatment Program H0001 Alcohol and/or Drug Assessment $152.91 Per assessment H0004 Individual Outpatient Therapy $21.54 Per 15 minute increment Can only be billed once per 12-months per participant per provider unless there is more than a 30 day break in treatment. Providers may not bill for more than six units per day per participant. N/A Cannot bill with H0015 or H2036 (billed by PT 50) H0005 Group Oupatient Therapy $42.00 Per 60-90 minute session Provider may not bill for more than one Level I Group counseling session per day per participant. Cannot bill with H0015 or H2036 (billed by PT 50) H0016 Methadone Services H0020: MAT Initial induction: Alcohol/Drug Services; Medical/Somatic (Medical Intervention in Ambulatory Setting) $215.36 Initial Induction period Methadone Maintenance $66.51 Per Week Provider may bill once per seven days only in the first week of treatment or after a break in treatment of 6 months. Provider may bill once per seven days when the patient has been seen at least once during the month; Providers may bill with Induction during the first week only. Cannot bill with E&M codes. Cannot bill with H0014 (billed by PT 50). Cannot bill with H0047. Cannot bill with H0014 (billed by PT 50). W9520 Methadone guest dosing $9.50 Per day receiving medication at guest program Guest dosing may be billed once per day that the patient is receiving their medication at the guest dosing program. One patient is eligible for up to 30 days of guest dosing per year. Additional days may be used with clinical reasoning. N/A 1

Buprenorphine Services Ongoing services (Buprenorphine/Naloxone): H0047 Alcohol/Other Drug Abuse Services, Not Otherwise Specified $59.12 Per Week Provider may bill once per seven days when the patient has been seen at least once during the month; Providers may bill with Induction during the first week only. Cannot bill with H0020. Cannot bill with H0014 (billed by PT 50) W9521 Buprenorphine guest dosing $8.45 Per day receiving medication at guest program Guest dosing may be billed once per day that the patient is receiving their medication at the guest dosing program. One patient is eligible for up to 30 days of guest dosing per year. Additional days may be used with clinical reasoning. N/A Medication management provided by Physicians, Nurse Practitioners, and Physician Assistants may be reimbursed using E&M codes. 99211: MAT Ongoing (Evaluation and Management, including Rx -Minimal) $21.99 Per visit 99212: MAT Ongoing (Evaluation and Management, including Rx -Straight $44.57 Per visit 99213: MAT Ongoing (Evaluation and Cannot bill with H0016. Cannot $73.65 Per visit For most providers and most participants, twelve Management, including Rx -Low bill with H0014 (billed by PT times a year will be sufficient. 99214: MAT Ongoing (Evaluation and Management, including Rx -Moderately $108.50 50). Per visit MAT Ongoing (Evaluation and 99215: Management, including Rx -Highly complex) $146.22 Per visit All lab tests are included in the bundled rate for OTPs. OTPs negotiate their rates with labs directly. Provider Type 50: OHCQ Certified of Licensed Substance Use Disorder Treatment Program H0001 Alcohol and/or Drug Assessment $152.91 Per assessment Can only be billed once per 12-months per participant per provider unless there is more than a 30 day break in treatment. N/A 2

H0004 Individual Outpatient Therapy $21.54 Per 15 minute increment Providers may not bill for more than six units per day per participant. Cannot bill with H0015 or H2036. Cannot be billed by a PT 50 concurrent with any PT 32 claims. H0005 Group Outpatient Therapy $42.00 Per 60-90 minute session Provider may not bill for more than one Level I Group counseling session per day per participant. Cannot bill with H0015 or H2036. Cannot be billed by a PT 50 concurrent with any PT 32 claims. H0015 Intensive Outpatient (IOP) $134.60 Per diem with a minimum of 2 hours of service per day Providers may bill for maximum of 4 days per week. Services for participants who require a minimum of 9 hrs of service per week for an adult and 6 hrs per week for adolescents. Cannot bill with H0004, H0005, or H2036 H2036 Partial Hospitalization $139.98 Per diem Providers may bill once per day and sessions shall be a minimum of 2 hours per day. Services for participants who require 20 weekly hours of structured outpatient treatment. Cannot bill this with H0004, H0005, or H0015 H2036: Modifier 22 Partial hospitalization (6+ hrs/day of services) $226.13 Per diem Providers may bill one per day and sessions shall be a minimum of 6 hours per day. Services for participants who require 20 weekly hours of structured outpatient treatment. Cannot bill this with H0004, H0005, or H0015 H0014 ADAA Certified Ambulatory Detox Program $75.38 Per diem Max of 5 days. Cannot be billed concurrent with any PT 32 claims. 3

Provider Type 50s that employ DATA 2000 WAIVED PRACITIONERS may be reimbursed for Medication Assisted Treatment for SUD using E&M codes. 99201: 99202: 99203: 99204: 99205: 99211: MAT Initial Intake (Evaluation and Management, Including Rx-Minimal, new patient) MAT Initial Intake (Evaluation and Management, Including Rx-Straight forward, new patient) MAT Initial Intake (Evaluation and Management, Including Rx-Low complexity, new patient) MAT Initial Intake (Evaluation and Management, Including Rx Moderately complex, new patient) MAT Initial Intake (Evaluation and Management, Including Rx-Highly complex, new patient) MAT Ongoing (Evaluation and Management, including Rx -Minimal) $45.37 Per visit $76.01 Per visit $109.40 Per visit $166.09 Per visit $208.77 Per visit $21.99 Per visit For most providers and most participants, twelve times a year will be sufficient. Cannot bill with H0014. Cannot be billed by a PT 50 concurrent with any PT 32 claims. 99212: 99213: 99214: 99215: MAT Ongoing (Evaluation and Management, including Rx -Straight forward) $44.57 Per visit MAT Ongoing (Evaluation and Management, including Rx -Low $73.65 Per visit complexity) MAT Ongoing (Evaluation and Management, including Rx -Moderately $108.50 Per visit complex) MAT Ongoing (Evaluation and Management, including Rx -Highly $146.22 Per visit complex) 4

Medication Assisted Treatment BUPRENORPHINE The codes below apply to PT 32, or PT 50 that is administering buprenorphine directly to patients. When the provider has ordered and paid for the drug directly through the manufacturer, the provider will reimburse based on the dosage of the administered medication to the patient. The J codes may NOT be used when prescribing the medication, or when the medication is obtained from the pharmacy where the point of sale occurred. ZUBSOLV J0572: Modifier 51 J0572 (No modifier) J0573 (No modifier) SUBOXONE J0572: Modifier SC J0574 (No modifier) BUNAVAIL J0572: J0572: Modifier HF J0573: Modifier 51 J0573: Modifier SC J0574: Modifier 51 J0574: Modifier SC Service Description Rate Unit Service Limits ZUBSOLV must include NDC: 54123-0914-30 ZUBSOLV must include NDC: 54123-0929-30 ZUBSOLV must include NDC: 54123-0957-30 Suboxone Film Must include NDC: 12496-1202-03 Suboxone Film Must include NDC: 12496-1208-03 Bunavail must include NDC: 59385-0012-01 Bunavail: must include NDC 59385-0012-30 Bunavail must include NDC: 59385-0014-01 Bunavail must include NDC: 59385-0014-30 Bunavail must include NDC: 59385-0016-01 Bunavail must include NDC: 59385-0016-30 $3.85 1.4-0.36 mg tablet $7.74 2.9-0.71 mg tablet $7.77 5.7-1.4 mg tablet $4.30 2 mg $7.72 8 mg $7.65 2.1-0.3 mg film $7.79 2.1-0.3 mg film $8.03 4.2-0.7 mg film $7.72 4.2-0.7 mg film $16.06 6.3-1 mg film $15.47 6.3-1 mg film May be reimbursed in combinations that reach the correct clinical dose. 5

SUBUTEX J0571: Modifier 51 J0571 (no modifier) Service Description Rate Unit Service Limits Subutex 2 mg: NDCs below $0.92 2 mg Subutex 8 mg: NDCs below $1.42 8 mg Subutex NDC codes NDC Drug Name Price 00054-0176- 13 BUPRENORPHINE 2 MG TABLET S $0.92 00054-0177- 13 BUPRENORPHINE 8 MG TABLET S $1.42 00093-5378- 56 BUPRENORPHINE 2 MG TABLET S $0.92 00093-5379- 56 BUPRENORPHINE 8 MG TABLET S $1.42 00228-3153- 03 BUPRENORPHINE 8 MG TABLET S $1.42 00228-3156- 03 BUPRENORPHINE 2 MG TABLET S $0.92 00378-0923- 93 BUPRENORPHINE 2 MG TABLET S $0.92 00378-0924- 93 BUPRENORPHINE 8 MG TABLET S $1.42 50383-0924- 93 BUPRENORPHINE 2 MG TABLET S $0.92 50383-0930- 93 BUPRENORPHINE 8 MG TABLET S $1.42 6

VIVITROL The codes below apply to community based providers that are administering vivitrol directly to patients. When the provider has ordered and paid for the drug in advance, directly through the manufacturer, medicaid will reimburse based on the dosage of the administered drug to the Medicaid patient. The J codes may NOT be used when prescribing the medication, or when the medication is obtained from the pharmacy where the point of sale occurred. Service Description Rate Unit J2315 Vivitrol: Must include NDC 65757-- 0300-01 $3.45 Per unit 96372-HG Therapeutic Injection $20.57 Per injection Any DATA 2000 Waived Practitioner (MD, NP, PA) and Local Health Department with DATA 2000 Waived Practitioners Service Description MAT Initial Intake (Evaluation and Management, 99201 $45.37 Per visit Including Rx-Minimal, new patient) MAT Initial Intake (Evaluation and Management, 99202 $76.01 Per visit Including Rx-Straight forward, new patient) MAT Initial Intake (Evaluation and Management, 99203 $109.40 Per visit Including Rx-Low complexity, new patient) MAT Initial Intake (Evaluation and Management, 99204 $166.09 Per visit Including Rx-Moderately complex, new patient) MAT Initial Intake (Evaluation and Management, 99205 $208.77 Per visit Including Rx-Highly complex, new patient) 99211 MAT Ongoing (Evaluation and Management, including Rx -Minimal) $21.99 Per visit 99212 MAT Ongoing (Evaluation and Management, including Rx -Straight forward) $44.57 Per visit Rate Service Limits Maximum of 380 units per dose. Minimum age of use is 18. Limit one injection per month. Unit 7

Service Description Rate Unit 99213 MAT Ongoing (Evaluation and Management, including Rx -Low complexity) $73.65 Per visit 99214 MAT Ongoing (Evaluation and Management, including Rx -Moderately complex) $108.50 Per visit 99215 MAT Ongoing (Evaluation and Management, including Rx -Highly complex) $146.22 Per visit 8

Provider Type 54: IMD Residential SUD for Adults H0001 Alcohol and/or Drug Assessment $ 152.91 Per assessment Can only be billed if the patient is NOT assessed to meet ASAM Residential Levels of Care 3.3, 3.5, 3.7, or 3.7WM. Cannot be billed within 7 days of W7330, W7350, W7370, or W7375 W7330 ASAM Level 3.3 $ 189.44 Per diem W7350 ASAM Level 3.5 $ 189.44 Per diem W7370 ASAM Level 3.7 $ 291.65 Per diem W7375 ASAM Level 3.7WM $ 354.67 Per diem RESRB Room and Board $ 45.84 Per diem Cannot be billed with any community based SUD codes on this fee schedule with the exception of H0020 and H0047. Cannot be billed with any mental health community based services except for date of admission or for services rendered by a community based psychiatrist. Cannot be billed with any drug screen/ test codes. Administrative Days for Residential SUD for Adults W7330-HG W7350-HG W7370-HG Service Description Rate Unit Service Limits ASAM Level 3.3 Admin Day for Consumer Awaiting Community Services ASAM Level 3.5 Admin Day for Consumer Awaiting Community Services ASAM Level 3.7 Admin Day for Hospitalized Consumer $ 189.44 Per diem $ 189.44 Per diem $291.65 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting community services. combination for a short-term, clinically indicated bed hold if the consumer is awaiting community services combination to hold the bed if the consumer has been hospitalized for a short-term stay. Short term stay decided by clinical services. 9

Service Description Rate Unit Service Limits W7370-SC ASAM Level 3.7 Admin Day for Consumer Awaiting 3.5 or 3.3 Bed $ 189.44 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting a 3.5/3.3 bed. W7375-HG ASAM Level 3.7WM Admin Day for Hospitalized Consumer $354.67 Per diem combination to hold the bed if the consumer has been hospitalized for a short-term stay. Short term stay decided by clinical services. W7375-SC ASAM Level 3.7WM Admin Day for Consumer Awaiting 3.7 Bed $291.65 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting a 3.7 bed. W7375-51 ASAM Level 3.7WM Admin Day for Consumer Awaiting 3.3 or 3.5 Bed $ 189.44 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting a 3.5/3.3 bed. Provider Type 55: ICF-A (Under 21) 0100 (rev code) Residential Services (child and adolescent) cost settled Per diem 10

Drug Testing s Labs may not bill Medicaid for tests that are sent by OTPs (Provider Type 32) or Adult Residential Service providers (Provider Type 54) as those lab drug tests are included in the providers' bundled/ inclusive rates. Service Description Rate Unit Service Limits Presumptive Drug Testing. Drug test(s), presumptive, any number of drug 80305 may be billed by CLIA classes; any number of devices or procedures, (eg, waived providers. immunoassay) capable of being read by direct 80305 $10.70 Per test optical observation only (eg, dipsticks, cups, cards, Limit of one presumptive test cartridges), includes sample validation when per patient per day. performed, per date of service Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, 80306 immunoassay) read by instrument-assisted direct optical observation (eg, dipsticks, cups, cards, $14.28 Per test cartridges), includes sample validation when performed, per date of service Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers (eg, 80307 immunoassay, enzyme assay, TOF, MALDI, $57.10 Per test LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when performed, per date of service Definitive Drug Testing. Must be performed by Labs Only: Selection must reflect Medical necessity Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative and quantitative, all sources, includes specimen validity testing, per day, per # of drug classes as listed below. Service Description Per day, 1-7 drug class(es), including matabolite(s) G0480 $90.97 Per test if performed. Rate Unit Service Limits 80306 and 80307 may be billed by providers with appropriate CLIA and adequate equipment and laboratory classifications. See CMS guidance for additional information: https://www.cms.gov/regulation s-and- Guidance/Legislation/CLIA/ind ex.html?redirect=/clia. Limit of one presumptive test per patient per day. These drug tests may only be billed by Provider Type 10, Laboratories. 11

Service Description Per day, 8-14 drug class(es), including G0481 $124.49 Per test metabolite(s) if performed. Rate Unit Laboratories. Limit of one definitive test per patient per day. 12